Form 4: Phibro CEO Sells $727K in Stock Under 10b5-1 Plan

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold over $727,000 worth of Class A Common Stock through pre-arranged trading plans.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp, along with BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 14,080 shares were sold across three transactions in February 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On February 13, 2026, 7,040 shares were sold at a weighted average price of $51.9633, with prices ranging from $51.61 to $52.345.
• On February 18, 2026, 6,824 shares were sold at a weighted average price of $51.3774, with prices ranging from $50.90 to $51.875.
• Also on February 18, 2026, an additional 216 shares were sold at a weighted average price of $51.9688, with prices ranging from $51.90 to $52.05.
• Following these transactions, BFI Co., LLC beneficially owns 36,680 shares indirectly, and Jack Bendheim directly owns 16,840 shares.
• Jack Bendheim exercises voting and dispositive power over BFI Co., LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sales are pre-planned, significant divestment by a key insider and major shareholder can raise questions about future growth prospects or valuation, even if not indicative of immediate negative news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to immediate new negative information.

Negatives

• Significant insider selling by the President and CEO, a Director, and a 10% owner, totaling approximately $727,526.
• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence or a signal that the stock price may be nearing a peak.

Risks

• Potential negative market perception due to significant insider selling by key management and a major shareholder.
• Reduced alignment of interests between the CEO/10% owner and common shareholders as their direct and indirect holdings decrease.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI.
• Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider selling, even when conducted under a pre-arranged 10b5-1 plan, is often scrutinized by investors. While 10b5-1 plans are designed to allow insiders to sell shares without being accused of trading on material non-public information, significant sales by a CEO and 10% owner can still be perceived as a signal regarding the company's valuation or future prospects, potentially influencing market sentiment for Phibro Animal Health Corp relative to its peers in the animal health sector.

Comparison to Industry Standards

• Insider selling by a CEO and 10% owner, even under a 10b5-1 plan, is generally viewed with caution by the market. For example, similar sales by executives at competitors like Zoetis Inc. or Elanco Animal Health Inc. would likely draw similar scrutiny, as they represent a reduction in direct equity exposure by key decision-makers.
• The total value of sales, approximately $727,526, represents a notable amount, though its significance depends on the overall size of the insider's holdings and the company's market capitalization. Without specific comparable insider sales data from direct competitors, it is difficult to benchmark the magnitude precisely, but it is a material amount for an individual.

Related Party Transactions

• The sales were conducted by BFI Co., LLC, which is indirectly controlled by Jack Bendheim, the CEO, Director, and 10% owner. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Employees: No direct impact mentioned, but a decline in stock price could affect employee stock options or morale.

Next Steps

• The filing does not explicitly mention future actions or milestones beyond the execution of the 10b5-1 plan.

Key Dates

Recommendation

While the insider selling by the CEO and a 10% owner is a negative signal, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates some of the immediate concern that it is based on new, undisclosed negative information. However, it still represents a reduction in insider ownership, which can be a drag on sentiment. Without additional fundamental news, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and insider activity closely.

Keywords

Phibro Animal Health, PAHC, Insider Selling, Form 4, Jack Bendheim, BFI Co. LLC, 10b5-1 Plan, Stock Sale, CEO, Director, 10% Owner, Equity Transaction